======= TMEM189-UBE2V1 ======= == Gene Information == * **Official Symbol**: N/A * **Official Name**: N/A * **Aliases and Previous Symbols**: N/A * **Entrez ID**: N/A * **UniProt**: N/A * **Interactions**: [[https://thebiogrid.org/search.php?search=TMEM189-UBE2V1&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TMEM189-UBE2V1|Open PubMed]] * **OMIM**: N/A == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Has no ubiquitin ligase activity on its own. The UBE2V1- UBE2N heterodimer catalyzes the synthesis of non-canonical poly- ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:21512573, ECO:0000269|PubMed:9305758, ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9580084, ECO:0000269|PubMed:9705497}. |Kua-UEV1 localn| |UQ con| |protein K63-linked ubiquitination| |ubiquitin conjugating enzyme activity| |postreplication repair| |protein polyubiquitination| |DNA repair| |protein ubiquitination| |DNA metabolic process| |protein modification by small protein conjugation| |cellular response to DNA damage stimulus| |protein modification by small protein conjugation or removal| |cellular response to stress| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.65| |[[:results:exp507|Monensin 0.3μM R08 exp507]]|-2.45| |[[:results:exp457|Bisphenol F 50μM R08 exp457]]|-2.19| |[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-2.12| |[[:results:exp516|Pyrazinamide 100μM R08 exp516]]|-2.07| |[[:results:exp164|Q15 1 to 2μM on day4 R04 exp164]]|-2.04| |[[:results:exp77|Prochlorperazine 5.2μM R02 exp77]]|-1.96| |[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-1.93| |[[:results:exp484|GSK-J5 1.5μM R08 exp484]]|-1.87| |[[:results:exp79|Q15 2.7μM R02 exp79]]|-1.8| |[[:results:exp215|Colchicine 0.009μM R05 exp215]]|2.75| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: N/A ^Tissue^Fraction Of Cell Lines Where Essential^ == Essentiality in NALM6 == * **Essentiality Rank**: 5004 * **Expression level (log2 read counts)**: 2.74 {{:chemogenomics:nalm6 dist.png?nolink |}}